Alexander Bershadskiy, MD


Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Shannon N. Westin, MD, MPH


Shannon N. Westin, MD, MPH, Discussed the Wee1 Inhibitor Adavosertib for PARPi-Resistant Ovarian Cancer

CancerNetwork® sat down with Shannon N. Westin, MD, MPH, at the 2021 ASCO Annual Meeting to talk about the use of adavosertib in PARP inhibitor–resistant ovarian cancer.

Alberto Calvo-García, PharmG


Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data

Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.

Abdulraheem Yacoub, MD


Abdulraheem Yacoub, MD, on Advancing Outcomes for Patients With Myelofibrosis and Myeloproliferative Neoplasms

CancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.

Sandra Cuellar, PharmD, BCOP, FASHP


Expert Commentary on the Product Profile of Margetuximab for HER2-Positive Breast Cancer

In an interview with ONCOLOGY®, Sandra Cuellar, PharmD, BCOP, FASHP, offers a comprehensive review of real-world treatment considerations of margetuximab as therapy for adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 being for metastatic disease.

Bhupesh Parashar, MD


Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional Fractionation

ABSTRACT Symptomatic spinal metastasis is a frequent complication of cancer that had been treated, until relatively recently, with primitive techniques to modest radiation dose levels, with a baseline assumption of limited survival and poor patient performance in that setting. In the era of targeted and personalized therapies, many patients are living longer and more functionally and are able to manage their disease on the model of chronic illness. Given these developments, an attractive option is the use of stereotactic body radiation therapy (SBRT) to deliver high biologically effective doses of radiation conformally to maximize the palliative gains of treatment. However, randomized data to guide practice are scarce. We review the extant literature and present an algorithmic approach to selecting patients with metastatic disease for palliative spinal SBRT favoring the results of available randomized studies and remaining within the safety constraints supported by evidence from randomized trials.

Robert L. Coleman, MD, FACOG, FACS


The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer Treatment

The panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.

Tolga Tuncer, MD


Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma

This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.

Cristina Gasparetto, MD


Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM

The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.

Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences


ONCOLOGY® Looks to Conference Agendas for Current Trends

"Witnessing the resiliency of the oncology community in the face of challenges to both patients and their providers builds momentum in the community and is sure to lead to better outcomes going forward."

Douglas Blayney, MD


Douglas Blayney, MD, on Reducing the Incidence of CIN with Plinabulin Plus Pegfilgrastim

Plinabulin in combination with pegfilgrastim reduced the incidence of chemotherapy-induced neutropenia, compared with pegfilgrastim alone, in patients with breast cancer undergoing chemotherapy with docetaxel, doxorubicin, and cyclophosphamide.

Solange Peters, MD, PhD


Solange Peters, MD, PhD, Reviews Evolving Treatment Trends in Lung Cancer

“Be courageous: Your work will be recognized, and everything is about [the] work in the end.”

Lisa Sprod, PhD, MPH


Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier

Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.

Amy A. Ayers, MPH


Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical Trials

A multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.

Davit Dallakyan MD, PhD


How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.

Farshid Dayyani, MD, PhD


Farshid Dayyani, MD, PhD, Discusses Multidisciplinary Approach to Research on Treatment for Gastroesophageal Adenocarcinoma

A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.

Daniel Ahn, DO


Patient Scenario: A 66-Year-Old Male With BRAF-Mutant mCRC

Daniel Walden, MD, presents the scenario of a 66-year-old man diagnosed with BRAF V600E-mutant metastatic colorectal cancer to the expert panel for discussion.

Lilit Sargsyan, MD


How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.

Raoul S. Concepcion, MD, FACS


Optimization of Genetic Testing for mCRPC

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.